Skip to main content

Mark Denison Archives

Dolly Parton donates $1 million to pediatric infectious disease research at Vanderbilt University Medical Center

Jun. 15, 2022—Dolly Parton is donating $1 million to pediatric infectious disease research at Vanderbilt University Medical Center to help in the fight against serious infectious diseases such as coronavirus that have worldwide ramifications.

Read more


Resistance to COVID-19 drug detected in lab study

May. 10, 2022—Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

Read more


Faculty awards honor teaching, clinical, research excellence

May. 5, 2022—The 2022 Vanderbilt University School of Medicine Academic Enterprise Awards for Excellence in Teaching, Extraordinary Performance of Clinical Service, and Outstanding Contributions to Research were presented April 29 during the annual spring faculty meeting.

Read more


VUMC a national leader in physician-scientist training

Apr. 21, 2022—Physician-scientists from Vanderbilt University Medical Center were well represented at the recent annual meeting of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and the American Physician-Scientist Association.

Read more


VUMC researchers involved in developing Moderna’s COVID-19 vaccine featured in Smithsonian exhibit

Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.

Read more


Seven from VUMC among most highly cited researchers

Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


VUMC research contributed to first COVID-19 pill now under review

Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

Read more


COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Read more


New study supports remdesivir as COVID-19 treatment

Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Read more


Medical Scientist Training Program adapts to COVID-19 challenges

Apr. 16, 2020—The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.

Read more


VUMC team aids development of potential antiviral drug for COVID-19

Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more